Data from several studies suggested that EGFR and KRAS mutations were associated with poor prognosis of NSCLC patients.[10,11] EGFR-TKs show greater treatment benefits for NSCLC patients with EGFR mutation rather than KRAS mutation. Here, KRAS is linked to non-small cell lung carcinoma.